Summit Therapeutics to Present New Preclinical Data on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Summit Therapeutics to Present New Preclinical Data on Utrophin Modulator Programme at PPMD Connect Conference
  • Treatment with SMT C1100 and SMT022357 results in increased utrophin along the length of muscle fibers leading to disease reduction in DMD models

OXFORD, United Kingdom, June 19, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq: SMMT ), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection, announces new preclinical data on its lead utrophin modulator SMT C1100 and second generation compound SMT022357, which are in development for the treatment of all patients with DMD. These data are being reported at the annual Parent Project Muscular Dystrophy ('PPMD') Connect conference being held between 18-21 June in Washington, DC.

The studies conducted in an in vivo model of DMD showed that after daily oral treatment with either SMT C1100 or SMT022357, utrophin was localized along the entire length of muscle fiber membrane (sarcolemma). These data are supportive of the utrophin modulation mechanism as they suggest that the small molecule compounds are increasing utrophin transcription in myonuclei along the entire length of muscle fibers. The studies also showed that the dystrophin associated protein complex ('DAPC') was restored with β-dystroglycan and β-dystrobrevin, both members of the DAPC, being expressed at the membrane of all fibers. The DAPC plays a structural role in muscle fibers and it is significantly reduced in membranes of muscle fibers in boys with DMD.

"The ability to maintain utrophin along the entire length of muscle fibers, combined with the restoration of the DAPC, is essential if this approach is to reduce the progression of this devastating muscle disease. These data strongly support utrophin modulation as a valuable mechanism to treat DMD," said Professor Dame Kay E. Davies of the University of Oxford . "There is tremendous therapeutic potential for utrophin modulation in DMD given there is no approved therapy applicable for all patients with DMD with many of the other clinical candidates focused on disease modifying approaches restricted to sub-populations of specific dystrophin mutations."

Utrophin is structurally and functionally similar to dystrophin, the protein which is absent in boys with DMD. Utrophin is normally expressed by everyone during muscle development and repair. By modifying utrophin expression to be constantly produced in the muscles of boys with DMD, this potentially disease-modifying approach has the potential to circumvent the need for dystrophin in all patients with this disease. Summit is currently evaluating SMT C1100, a first-generation utrophin modulator, in a Phase 1b clinical study.

A copy of the presentation to be given at the PPMD Connect Conference is now available from the Company's website, www.summitplc.com .

- END -

About DMD and Utrophin Modulation

DMD is a progressive muscle wasting disease that affects around 50,000 boys in the developed world. The disease is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles. There is currently no cure for DMD and life expectancy is into the late twenties. Utrophin protein is functionally and structurally similar to dystrophin. In preclinical studies, the continued expression of utrophin has meaningful, positive effect on muscle performance. Utrophin modulation has the potential to slow down or even stop the progression of DMD, regardless of the underlying dystrophin mutation. It is also expected that utrophin modulation could potentially be complementary to other therapeutic approaches for DMD.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter ( @summitplc ).

For more information, please contact:

Summit Therapeutics  
Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951
Erik Ostrowski (US office)  +1 617 294 6607
   
Cairn Financial Advisers LLP  
(Nominated Adviser)  
Liam Murray / Tony Rawlinson Tel: +44 (0)20 7148 7900
   
N+1 Singer   
(Broker)  
Aubrey Powell / Jen Boorer  Tel: +44 (0)20 7496 3000
   
MacDougall Biomedical Communications  
(US media contact) Tel: +1 781 235 3060
Michelle Avery mavery@macbiocom.com
   
Peckwater PR  
(Financial public relations, UK) Tel: +44 (0)7879 458 364 
Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk

Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, the timing of clinical results and expectations regarding the sufficiency of our cash balance to fund operating expenses and capital expenditures, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 47

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 101

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 150

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 92

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

Macquarie's Optimistic Outlook for Chinese Internet Stocks

Updated Category News Views 155

Macquarie's Recent Upgrades in the Chinese Internet Sector Macquarie has taken a positive stance on various Chinese internet stocks, highlighting the stronger fundamentals and increased earnings visibility that have emerged in the sector. Analysts believe that ongoing support from the government will further bolster these companies, leading to enhanced growth...

Continue Reading
Highmark Health's Impressive Financial Growth and Future Outlook

Updated Category News Views 238

Highmark Health Reports Impressive Financial Results In a remarkable update, Highmark Health shared its consolidated financial outcomes for the first half of 2025, revealing a revenue of $16.5 billion, alongside a net income of $329 million. This performance is indicative of the organization's robust positioning within the healthcare sector, despite facing ongoing...

Continue Reading
Roblon Reports Steady Q1 Performance Amid Market Challenges

Updated Category News Views 136

Roblon A/S Delivers Steady Financial Results in Q1 2024/25 Roblon’s revenue and earnings for the first quarter of 2024/25 meet expectations The Board of Directors at Roblon A/S has reviewed and approved the interim report reflecting the company’s performance over the initial three months of the financial year 2024/25. This period showcased resilient revenue figures,...

Continue Reading
Weis Markets Achieves Notable Growth in Third Quarter 2025

Updated Category News Views 188

Weis Markets Shows Strong Third Quarter Performance Weis Markets, Inc. (NYSE: WMK) has reported impressive financial results for its third quarter. The company saw an increase of 2.5% in comparable store sales excluding fuel, showcasing its resilience in a fluctuating economic landscape. Overview of Third Quarter Results In the 13-week period ending September 27, 2025,...

Continue Reading
Innovative Renal Care Faces Investigation Over Major Data Breach

Updated Category News Views 156

Innovative Renal Care Under Investigation for Data Breach In recent developments, Innovative Renal Care has come under scrutiny due to a significant data breach that has alarmed both the company and its patients. The investigation, spearheaded by Federman & Sherwood, seeks to uncover the full extent of the incident and understand its implications. Details of the Data...

Continue Reading